Familial Chylomicronemia Syndrome Treatments Compared
2 FDA-approved drugs, side by side from the current prescribing labels. Newest label Aug 2026. Checked October 9, 2026.
Two drugs are FDA-approved for adults with familial chylomicronemia syndrome (FCS), and both work the same way, by silencing the APOC3 gene in the liver so the body can clear triglycerides. Tryngolza (olezarsen) is a self-injection once a month with an autoinjector; Redemplo (plozasiran) is a self-injection once every 3 months with a prefilled syringe. In separate placebo-controlled trials, Tryngolza lowered triglycerides 43% more than placebo at 6 months and Redemplo 59% more at 10 months, but the trials used different time points, averages and entry rules, so those numbers do not rank the drugs. Both are taken alongside a very low-fat diet of 20 grams of fat or less a day, and neither is approved for children.
2 approved familial chylomicronemia syndrome treatments at a glance
How each drug is given, how often, who it is approved for and when it was first approved, from the current FDA label.
A year on each familial chylomicronemia syndrome treatment
Every dose in a year, drawn to the label schedule, so you can see at a glance how often each one is given.
Counts follow the label schedule for a full year on the maintenance dose. Drugs given in cycles or adjusted to blood tests have no fixed count, so their schedule is written out instead.
What the pivotal familial chylomicronemia syndrome trials showed
The primary result from the trial each FDA approval rests on, as reported on the label.
Familial Chylomicronemia Syndrome treatment side effects and warnings
None of these drugs carries a boxed warning. Each label's main precautions are listed.
Help paying for familial chylomicronemia syndrome treatment
Drugmaker copay and free-drug programs, plus charity funds for the condition, checked every week.
Familial Chylomicronemia Syndrome treatment questions people ask
Tryngolza vs Redemplo: what is the difference for familial chylomicronemia syndrome?
Both lower apoC-III, the protein that stops the body from clearing triglycerides, but they are built differently and dosed on different schedules.
How it is given: Tryngolza is 80 mg under the skin once a month from an autoinjector. Redemplo is 25 mg under the skin once every 3 months from a prefilled syringe. Both can be given at home after training.
Who it is for: both are approved for adults with FCS, alongside a low-fat diet. Tryngolza is also approved, at a lower dose, for severe hypertriglyceridemia.
Safety: neither has a boxed warning. Tryngolza's label warns about allergic reactions and rises in liver enzymes and liver fat. Redemplo's label has no warnings section; high blood sugar, headache and nausea were the most common side effects.
Trial results: Tryngolza lowered triglycerides 43% more than placebo at 6 months. Redemplo lowered the median 59% more than placebo at 10 months. The trials were separate and measured differently, so these numbers do not show which drug works better.
More: Tryngolza drug page and Redemplo drug page
Source: FDA label for Tryngolza, DailyMed, effective July 2026; FDA label for Redemplo, DailyMed, effective August 2026
Which FCS drug lowers triglycerides more?
No trial has compared them. In its own trial, Tryngolza cut average triglycerides by 30% while placebo rose 12% at 6 months. In its trial, Redemplo cut median triglycerides by 80% against 17% on placebo at 10 months. Different time points, averaging methods and entry rules mean the percentages cannot be lined up as a ranking.
Do Tryngolza and Redemplo prevent pancreatitis in FCS?
Fewer people had pancreatitis attacks on both drugs than on placebo over 12 months, 1 of 22 on Tryngolza against 7 of 23, and 2 of 26 on Redemplo against 5 of 25. Both labels describe these as numerical differences from small trials, and neither drug's FCS approval says it prevents pancreatitis. Tryngolza's separate approval for severe hypertriglyceridemia does include reducing the risk of acute pancreatitis.
Can I stop the low-fat diet if I take Tryngolza or Redemplo?
No. Both labels say the drug is an add-on to diet, and both tell people with FCS to keep eating 20 grams of fat or less a day. Everyone in both trials stayed on that diet.
Is there an FCS treatment for children?
Not yet. Neither Tryngolza nor Redemplo is approved under age 18, and both labels say safety and effectiveness in children have not been established. An open-label study of Tryngolza in children aged 2 to 17 with FCS (NCT07727538) began in July 2026 and is recruiting about 12 children.
Is volanesorsen (Waylivra) available in the United States?
No. Volanesorsen, an earlier APOC3 drug from Ionis and Akcea, received a complete response letter from the FDA in August 2018, meaning it was not approved, and it is approved in Europe instead. Tryngolza, approved in December 2024, was the first FCS drug approved in the US.
More on Familial Chylomicronemia Syndrome at Trial Friend
Where every number on this page comes from
Approved-drug facts are from the current FDA prescribing information on DailyMed, with the label's effective date. Investigational-drug facts are from ClinicalTrials.gov and the sources named in each row.
- Tryngolza (olezarsen) prescribing information, Ionis Pharmaceuticals, label dated Jul 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
- Redemplo (plozasiran) prescribing information, Arrowhead Pharmaceuticals, label dated Aug 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
This page compares what the FDA labels and pivotal trials report. It is not medical advice, and no trial on this page compared these drugs with each other. Written and checked by Jason Hunter; the method is on the editorial standards page.